Effects of Multistrain Probiotic Supplementation on Glycemic and Inflammatory Indices in Patients with Nonalcoholic Fatty Liver Disease: A Double-Blind Randomized Clinical Trial

Journal of the American College of Nutrition

Volumn 35, Issue 6, 2016, Pages 500-505

  Sepideh, Abbaszadeh ^a   Karim, Parastouei ^b   Hossein, Afshari ^a   Leila, Rostami ^a   Hamdollah, Mahmoudi ^a   Mohammad E, Ghamarchehreh ^a   Mojtaba, Sepandi ^a   Mohammad, Samadi ^a   Ghader, Ghanizadeh ^a   Seyed Moayed, Alavian ^a  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

blood glucose; cytokines; fatty liver; probiotic

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; INTERLEUKIN 6; PROBIOTIC AGENT; TRACE ELEMENT; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; PLACEBO; TUMOR NECROSIS FACTOR;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BIOCHEMICAL ANALYSIS; BLOOD BIOCHEMISTRY; BODY MASS; CONTROLLED STUDY; DIET RESTRICTION; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCEMIC INDEX; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFLAMMATION; INSULIN RESISTANCE; ION EXCHANGE CHROMATOGRAPHY; LIFESTYLE MODIFICATION; MACRONUTRIENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; NUTRITIONAL ASSESSMENT; PHYSICAL ACTIVITY; PREVALENCE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; WAIST CIRCUMFERENCE; WAIST HIP RATIO; ADOLESCENT; AGED; ANALYSIS; ANTHROPOMETRY; BLOOD; DIET; GLUCOSE BLOOD LEVEL; INTESTINE FLORA; MICROBIOLOGY; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADOLESCENT; ADULT; AGED; ANTHROPOMETRY; BIOMARKERS; BLOOD GLUCOSE; DIET; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL MICROBIOME; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-6; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PLACEBOS; PROBIOTICS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84945241839     PISSN: 07315724     EISSN: 15411087     Source Type: Journal    
DOI: 10.1080/07315724.2015.1031355     Document Type: Article

References (26)

1. D.Labrecque, Z.Abbas, F.Anania, P.Ferenci, A.Ghafoor Khan, K.L.Goh:Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. World J Gastroenterol 1:1–29, 2012.
2. H.P.Monsour, C.T.Frenette, K.Wyne:Fatty liver:a link to cardiovascular disease its natural history, pathogenesis and treatment. Methodist Debakey Cardiovasc J 8:21–25, 2012.
3. R.Lomonaco, J.Chen, K.Cusi:An endocrine perspective of nonalcoholic fatty liver disease (NAFLD). Ther Adv Endocrinol Metab 2:211–225, 2011.
4. S.S.Lee, Y.S.Byoun, S.H.Jeong, Y.M.Kim, H.Gil, B.Y.Min, Seong MH, Jang ES, Kim JW:Type and cause of liver disease in Korea:single-center experience, 2005–2010. Clin Mol Hepatol 18:309–315, 2012.
5. D.Amarapurkar, P.Kamani, N.Patel, P.Gupte, P.Kumar, S.Agal:Prevalence of non-alcoholic fatty liver disease:population based study. Hepatology 6:161–163, 2007.
6. K.B.Lankarani, F.Ghaffarpasand, M.Mahmoodi, M.Lotfi, N.Zamiri, S.T.Heydari:Non-alcoholic fatty liver disease in southern Iran:a population based study. Hepat Mon 13:1–7, 2013.
7. N.Chalasani, Z.Younossi, G.Lavine, A.Diehl, E.Brunt, K.Cusi:The diagnosis and management of non-alcoholic fatty liver disease:practice guideline. Am J Hepatol 55:2005–2023, 2012.
8. A.K.Leamy, R.A.Egnatchik, J.D.Young:Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease. Prog Lipid Res 52:165–174, 2013.
9. J.K.Dyson, Q.M.Anstee, S.McPherson:Non-alcoholic fatty liver disease:a practical approach to treatment. Front Gastroenterol 1:1–10, 2014.
10. L.Abenavoli, E.Scarpellini, S.Rouabhia, C.Balsano, F.Luzza:Probiotics in NAFLD:which and when? Ann Hepatol 12:357–363, 2013.
11. A.Alisi, S.Ceccarelli, N.Panera, V.Nobili:Causative role of gut microbiota in non-alcoholic fatty liver disease pathogenesis. Front Cell Infect Microbiol 2:1–4, 2012.
12. Food and Agriculture Organization/World Health Organization:Report of a Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. 2001. Accessed at:http://www.who.int/foodsafety/publications/fs…/en/probiotics.pdf
13. A.Chatterjee, H.Bhattacharya, A.Kandwal:Probiotics in periodontal health and disease. J Indian Soc Periodontol 15:23–28, 2011.
14. H.Ejtahed, J.Mohtadi Nia, A.Homayouni Rad, M.Niafar, M.Asghari Jafarabadi, V.Mofid:The effects of probiotic and conventional yoghurt on diabetes markers and insulin resistance in type 2 diabetic patients:a randomized controlled clinical trial. Iran J Endocrinol Metabol 13:1–7, 2011.
15. D.Compare, P.Coccoli, A.Rocco:Gut–liver axis:the impact of gut microbiota on non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 22:471–476, 2012.
16. J.Bhathena, C.Martoni, A.Kulamarva, C.Tomaro-Duchesneau, M.Malhotra, A.Paul:Oral probiotic microcapsule formulation ameliorates non-alcoholic fatty liver disease in bio f1b golden Syrian hamsters. PloS ONE 8:1–9, 2013.
17. R.Aller, D.A.Deluis, O.Izaola, R.Conde, M.S.Gonzalez, B.Primo:Effect of a probiotic on liver amino transferase in nonalcoholic fatty liver disease patients:a double blind randomized clinical trial. Eur Rew Med Pharmacol Sci 15:1090–1095, 2011.
18. A.Shavakhi, M.Minakari, H.Firouzian, R.Assali, A.Hekmatdoost, G.Ferns:Effect of a probiotic and metformin on liver aminotransferases in non-alcoholic steatohepatitis:a double blind randomized clinical trial. Int J Prevent Med 4:531–537, 2013.
19. M.Manco, L.Putignani, G.F.Bottazzo:Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev 31:817–844, 2010.
20. P.D.Cani, J.Amar, M.A.Iglesias, M.Poggi, C.Knauf, D.Bastelica:Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56:1761–1772, 2007.
21. Y.Ritze, G.Bardos, A.Claus, V.Ehrmann, I.Bergheim, A.Schwiertz, S.C.Bischoff:Lactobacillus rhamnosus GG protects against non-alcoholic fatty liver disease in mice. PLoS ONE 9:1–8, 2014.
22. K.Laitinen, T.Poussa, E.Isolauri:Probiotics and dietary counselling contribute to glucose regulation during and after pregnancy:a randomized controlled trial. Br J Nutr 101:1679–1687, 2009.
23. P.Vajro, C.Mandato, M.R.Licenziati, A.Franzese, D.F.Vitale, S.Lenta:Effect of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr 52:740–743, 2011.
24. M.Malaguarnera, T.Antic, M.Giordano, G.Chisari, R.Acquaviva, S.Mastrojeni:Bifidobacterium longum with fructo-oligosaccharides in patients with non-alcoholic steatophepatitis. Dig Dis Sci 57:1884–1887, 2012.
25. Z.Mazloom, A.Yousefinejad, M.H.Dabbaghmanesh:Effect of probiotics on lipid profile, glycemic control, insulin action, oxidative stress, and inflammatory markers in patients with type 2 diabetes:a clinical trial. Iran J Med Sci 38:38–43, 2013.
26. P.D.Cani, S.Possemiers, T.Van de Wiele, Y.Guiot, A.Everard, O.Rottier:Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58:1091–1103, 2009.Received December 14, 2014; accepted March 16, 2015.